Actavis to buy Botox-maker Allergan

New York - Actavis plans to acquire Botox-maker Allergan for $66bn to create one of the top 10 global pharmaceutical companies by sales, the companies announced Monday.

The combination creates a heavyweight in opthalmology, neurosciences and medical aesthetics and puts an end to an aggressive rival bid for Allergan from Canada's Valeant Pharmaceuticals International.

The companies said the deal would result in $1.8bn in annual cost savings, improved marketing success by combining sales forces and expanded reach into key growth markets in Asia and Latin America.

"We will establish an unrivaled foundation for long-term growth, anchored by leading, world-class blockbuster franchises and a premier late-stage pipeline that will accelerate our commitment to build an exceptional, sustainable portfolio," said Brent Saunders, chief executive of Actavis.

Actavis will pay $219 per share for Allergan in a mix of cash and Actavis shares, with the deal totalling approximately $66 billion. Actavis is headquartered in Dublin and has administrative headquarters in the US in the state of New Jersey.

Meanwhile rival bidder Valeant announced it would not raise its bid. Valeant has pursued Allergan since April, but was repeatedly met with refusals to enter negotiations.

Three weeks ago, Valeant floated raising its bid by $10bn to $60bn by offering "at least $200 a share" for the US company.

Monday's transaction is subject to shareholder votes by both Actavis and Allergan. The companies expect the deal to close in the second quarter of 2015.

In early trade, Allergan shares jumped 6.7% to $211.86, Actavis rose 3.4% to $252.01 and Valeant advanced 0.3% to $134.61.


ZAR/USD
17.00
(-0.36)
ZAR/GBP
21.21
(-0.30)
ZAR/EUR
19.12
(-0.30)
ZAR/AUD
11.81
(-0.62)
ZAR/JPY
0.16
(-0.21)
Gold
1774.43
(-0.02)
Silver
18.05
(+0.69)
Platinum
807.99
(+0.12)
Brent Crude
42.92
(+2.64)
Palladium
1914.00
(+1.46)
All Share
54521.90
(-0.17)
Top 40
50179.89
(-0.26)
Financial 15
10150.02
(-0.64)
Industrial 25
76554.73
(+0.52)
Resource 10
50138.02
(-1.24)
All JSE data delayed by at least 15 minutes morningstar logo
Company Snapshot
Voting Booth
Please select an option Oops! Something went wrong, please try again later.
Results
I'm not really directly affected
18% - 1575 votes
I am taking a hit, but should be able to recover in the next year
23% - 2068 votes
My finances have been devastated
34% - 3087 votes
It's still too early to know what the full effect will be
25% - 2240 votes
Vote